BioSig Technologies, Inc. (BSGM)
| Market Cap | 99.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -52.23M |
| Shares Out | 32.14M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 12 |
| Last Price | $3.07 |
| Previous Close | $3.04 |
| Change ($) | 0.03 |
| Change (%) | 0.99% |
| Day's Open | 3.01 |
| Day's Range | 2.98 - 3.20 |
| Day's Volume | 117,482 |
| 52-Week Range | 2.79 - 12.19 |
Using targeted electrical signals to harness the body's natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called ...
The Company sees increased technology usage across its installed base and anticipates enrolling to at least 1500 cases by the end of 2021 44 physicians have conducted over 800 arrhythmia patient cases t...
BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardia...
BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that physicians at Mayo Clinic's campus in Phoenix, Arizona have started using the company's PURE EP System in patient cases treating cardiac arrhyt...
Westport, CT, April 27, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative biomedical signal proces...
MedTech company BioSig Technologies, Inc.'s (NASDAQ: BSGM) first commercial product — the PURE EP system — is gaining traction with physicians and patients. What Happened: BioSig's PURE EP system, which...
BioSig Technologies Inc (NASDAQ:BSGM), which is commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, ...
Two seasoned MedTech sales executives join the Company to lead regional rollouts of the PURE EP System (TM), an electrophysiology system for arrhythmia procedures Two seasoned MedTech sales executives j...
BioSig Technologies, Inc. (NASDAQ:BSGM) has announced the release of the PURE EP Software Version 4. The latest release builds on the main system capabilities of the PURE EP while improving the overall ...
Westport, CT, April 14, 2021 (GLOBE NEWSWIRE) -- The latest release represents the most advanced software version of the PURE EPTM System, signal processing technology for treatments of irregular heartb...
BioSig Technologies Inc (NASDAQ:BSGM) said it has completed enrollment in the PURE EP 2.0 clinical trial. The multi-center, prospective clinical trial was conducted at the Texas Cardiac Arrhythmia Insti...
Westport, CT, April 13, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platfo...
Westport, CT, April 09, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platfo...
BioSig Technologies Inc (NASDAQ:BSGM) has seen its PURE EP System featured in the new edition of leading electrophysiology trade publication, EP Lab Digest. This is the second time that the computerized...
Westport, CT, April 08, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platfo...
Using targeted electrical signals to harness the body's natural mechanisms to diagnose and treat a range of diseases Has commercialized its first product, a biomedical signal processing platform called ...
BioSig Technologies, Inc. (NASDAQ:BSGM) has announced that a top-rated leading hospital system has purchased the company's PURE EP systems for multiple campuses in its national network. “We are pleased ...
Westport, CT, April 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platfo...
Westport, CT, April 05, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platfo...
BioSig Technologies Inc (NASDAQ:BSGM) said that US Patent Office has allowed a utility patent covering its PURE EP noise-filtering technology. The medical technology firm, which specializes in commercia...
Westport, CT, March 30, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platfo...
BioSig Technologies Inc (NASDAQ:BSGM) founder, Chairman, and CEO Kenneth L. Londoner told investors on Monday that the commercial adoption of the company's first product called the PURE EP, which measur...
Westport, CT, March 29, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal proces...
Westport, CT, March 10, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platfo...
Westport, CT, March 09, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platfo...
BioSig Technologies, Inc. (NASDAQ:BSGM), has said the US Patent Office has allowed a utility patent that its majority-owned subsidiary NeuroClear Technologies, Inc. had exclusively licensed from the May...
Westport, CT, March 04, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platfo...
BioSig Technologies, Inc. (NASDAQ:BSGM) announced Tuesday that it has appointed Brenda Castrodad to lead its Human Resources department. The medical technology company seasoned executive noted that Cast...
Seasoned medtech executive to scale up the Company's organizational development upon the increase in demand for the evaluative installations of the PURE EP System™ Seasoned medtech executive to scale up...
BioSig Technologies, Inc. (NASDAQ:BSGM) said it has entered into three new evaluation agreements for the PURE EP System, its novel electrophysiology (EP) signal acquisition and analysis technology. The ...
New 90-day evaluation cycles enable hospitals to more rapidly assess the platform technology while also accelerating BioSig's commercial activities New 90-day evaluation cycles enable hospitals to more ...
Westport, CT, Jan. 27, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platfor...
PURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph Gallinghouse, M.D., Texas Cardiac Arrhythmia Institute PURE EP(tm) System to be highlighted in a Spotlight session by G. Joseph G...
Westport, CT, Jan. 14, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platfor...
Industry-leading smart glasses technology expected to enhance the utility of BioSig's PURE EP™ System signal processing platform. Remote servicing intended to enable continued installations, upgrades, a...
PURE EP(tm) system evaluation conducted under the leadership of Cardiologists Vinod Chauhan, M.D. and Deepak Gaba, M.D. Memorial Hospital is nationally recognized for its emphasis on innovation. PURE EP...
Westport, CT, Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing p...
NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous system disease NeuroClear is set to commence experiments aimed at developing therapies for autonomic nervous...
BioSig Technologies, Inc. was one of the sponsors for the Benzinga Global Small Cap Conference that took place on December 8-9, 2020. According to recent information published on WHO's 2019 Global Healt...
BioSig Technologies Inc (NASDAQ: BSGM), a medical device company, announced Friday a commercial milestone with respect to its FDA-approved PURE EP Systems. What Happened: Westport, Connecticut-based Bio...
Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence
Westport, CT, Dec. 10, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing p...
Company's flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020 Company's flagship product to be featured in live patient case...
BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Business Development Update Conference Call (Transcript)
Westport, CT, Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal process...
First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center
Westport, CT, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal process...
BioSig Technologies Inc. (NASDAQ: BSGM) was absolutely crushed on Monday after the company announced that it would halt its midstage coronavirus study.
Shares of Biosig Technologies Inc. plunged 39.0% in active morning trading Monday, enough to pace all Nasdaq decliners, after the medical technology company halted a trial of its COVID-19 treatment give...
Westport, CT, Oct. 26, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), ann...
About BSGM
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial... [Read more...]
| Industry Medical Devices | Founded 2009 |
| Stock Exchange NASDAQ | Ticker Symbol BSGM |
Analyst Forecasts
According to one analyst, the rating for BSGM stock is "Buy" and the 12-month stock price forecast is 13.00.